Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Microbial Immunity and Vaccines

Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs

A. Williams, N. P. Goonetilleke, H. McShane, Simon O. Clark, Graham Hatch, S. C. Gilbert, A. V. S. Hill
A. Williams
1Health Protection Agency, Porton Down, Salisbury
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. P. Goonetilleke
2Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. McShane
3Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon O. Clark
1Health Protection Agency, Porton Down, Salisbury
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham Hatch
1Health Protection Agency, Porton Down, Salisbury
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. C. Gilbert
2Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. V. S. Hill
2Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN
3Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: adrian.hill@well.ox.ac.uk
DOI: 10.1128/IAI.73.6.3814-3816.2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Tuberculosis is rising in the developing world due to poor health care, human immunodeficiency virus type 1 infection, and the low protective efficacy of the Mycobacterium bovis BCG vaccine. A new vaccination strategy that could protect adults in the developing world from tuberculosis could have a huge impact on public health. We show that BCG boosted by poxviruses expressing antigen 85A induced unprecedented 100% protection of guinea pigs from high-dose aerosol challenge with Mycobacterium tuberculosis, suggesting a strategy for enhancing and prolonging the efficacy of BCG.

Mycobacterium tuberculosis, the bacillus that causes tuberculosis, kills approximately 2 million people each year (15). The induction of type 1 cytokine-producing T cells is central to protection from disease. The bacillus Calmette-Guérin (Mycobacterium bovis BCG) is the only licensed vaccine against tuberculosis (2). Each year 80% of children born globally are vaccinated with BCG (http://www.who.int/inf-fs/en/fact104.html ). BCG affords significant protection from childhood and miliary tuberculosis but fails to protect adults from pulmonary disease, which is the major cause of mortality in the developing world (3, 5). BCG-mediated protection lasted 10 to 15 years after vaccination in a United Kingdom study, indicating that neonatal vaccination has negligible impact on the adult epidemic (8).

We have previously shown that BCG-induced T-cell responses can be significantly boosted in BALB/c mice (7) and rhesus macaques (6) by attenuated poxviruses expressing the major M. tuberculosis secreted antigen and mycolyl transferase, antigen 85A. In BALB/c mice, BCG followed by a single vaccination of modified virus Ankara (MVA) expressing antigen 85A (MVA85A), both given intranasally, produced significantly greater protection following an aerosol M. tuberculosis challenge than did vaccination with BCG alone. The level of protection observed was the highest induced by a vaccination regimen in this strain of mice. In rhesus macaques we observed that parenteral immunization with BCG and then MVA85A induced T-cell responses that could be further boosted by intradermal immunization with a recombinant fowlpox virus, FP9, also expressing Ag85A (FP9.Ag85A) (6). The promising levels of immunogenicity induced by parenteral BCG-MVA85A-FP9.Ag85A vaccination led us to test whether this regimen protected guinea pigs against M. tuberculosis aerosol challenge. In this species, survival is a stringent measure of protection. Previous studies of plasmid DNA and poxvirus vaccines in guinea pigs have shown protection equivalent to but not better than that of BCG used alone (A. Williams et al., unpublished).

Six Dunkin-Hartley guinea pigs (David Hall, Burton-on-Trent, United Kingdom) were vaccinated subcutaneously with 5 × 104 CFU BCG and then 4 weeks later vaccinated with 107 PFU MVA85A intradermally and then 4 weeks later with a further 107 PFU FP9.Ag85A. Six other animals were vaccinated with BCG only on the day of the MVA immunization, and six animals were sham immunized with saline. Six weeks after the FP9 immunization animals were challenged by aerosol using a Collison nebulizer and Henderson apparatus delivering approximately 500 CFU of M. tuberculosis (H37Rv) into the airways. Animals were killed at 26 weeks postchallenge or at the humane end point (20% loss of maximal body weight). All saline controls died before the experimental end point, whereas two/six BCG-vaccinated animals survived. However, all six BCG-MVA85A-FP9.Ag85A-vaccinated animals survived until the end of the experiment at 26 weeks (versus BCG, P = 0.018) (Fig. 1). Over the 26-week period following challenge, the average weight gain for the BCG-MVA85A-FP9.Ag85A-vaccinated animals was 156 g (range, +2 to +221 g) (Table 1). In contrast, in the saline group the average weight loss was 79 g (range, −9 to −118 g). All animals in this group were killed at the humane end point. In the BCG-vaccinated group there was an average weight gain of 48 g (range of −21 to +149 g).

Only one other vaccination approach has been reported to show significantly greater efficacy than BCG in guinea pigs, a recombinant BCG (10) of the Tice strain overexpressing, from an episomal plasmid, antigen 85B, a paralogue of antigen 85A. Seventy-five percent of guinea pigs administered this rBCG30 strain survived to 26 weeks after administration of a challenge dose of M. tuberculosis 25-fold lower than that used in our study (9). The poxvirus boosting strategy has several advantages over use of any new replicating BCG strain expressing an episomal plasmid. The efficacy of new strains of BCG is likely to be impaired by immunity to environmental mycobacteria, as appears to be the case with BCG, leading to little efficacy in older individuals in the developing world (1, 14). In contrast poxvirus vectors appear to use preexisting immunity to mycobacteria to enhance their own immunogenicity (12). Nonreplicating poxviruses have been used safely in human immunodeficiency virus-positive individuals (e.g., reference 4) and, unlike replicating bacterial vectors, will likely be usable in this important target population for a new tuberculosis vaccine. Finally, poxvirus boosting of BCG leads to markedly enhanced T-cell responses in animals (6, 7) and adult humans (12), providing an immune marker to facilitate vaccine development.

We have now shown that poxviruses expressing antigen 85A can significantly boost T-cell-induced responses in mice (7), rhesus macaques (6), and humans (12) and produce significantly greater protection than BCG alone when delivered intranasally in mice (7) and intradermally in guinea pigs. In humans MVA boosting of BCG was equally immunogenic in recently BCG-vaccinated individuals and those BCG vaccinated more than 10 years earlier (12), supporting the use of poxvirus boosting in teenagers as a means of tuberculosis prevention in adults.

Recombinant nonreplicating poxviruses are increasingly widely used in clinical trials of candidate prophylactic and therapeutic vaccines, including several studies in the developing world (4, 11, 13), and demonstrate an excellent safety record. Their strong immunogenicity and protective efficacy in animal models of tuberculosis disease identify BCG prime-poxvirus boost regimens as a leading approach to an improved tuberculosis vaccine, a view supported by ongoing clinical evaluation of such regimens (12).

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Kaplan-Meier curves of the survival of guinea pigs post-aerosol challenge with M. tuberculosis. Six animals per group were vaccinated with BCG, BCG-MVA85A-FP9.Ag85A, or saline.

View this table:
  • View inline
  • View popup
TABLE 1.

Changes in weight of animals from 1 week after aerosol challenge until the end of the experimental period

ACKNOWLEDGMENTS

We thank K. Gooch, P. D. Marsh, and R. Anderson for assistance and advice.

This work was supported by the European Commission, The Wellcome Trust, and the UK Department of Health.

FOOTNOTES

    • Received 23 August 2004.
    • Returned for modification 18 October 2004.
    • Accepted 20 December 2004.
  • Copyright © 2005 American Society for Microbiology

REFERENCES

  1. 1.↵
    Black, G. F., et al. 2002. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised control studies. Lancet359:1393-1401.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Calmette, A., A. Boquet, and L. Negre. 1924. Essais de vaccination contre l’infection tuberculeuse par voie buccale ches les petits animaux de laboratoire. Ann. Inst. Pasteur38:399-404.
    OpenUrl
  3. 3.↵
    Colditz, G. A., et al. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA271:698-702.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Cosma, A., et al. 2003. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine22:21-29.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Fine, P., I. Carneiro, J. Milstien, and C. J. Clements. 1999. Report of Department of Vaccines and Other Biologicals. World Health Organization, Geneva, Switzerland.
  6. 6.↵
    Goonetilleke, N. P., et al. Submitted for publication.
  7. 7.↵
    Goonetilleke, N. P., et al. 2003. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol.171:1602-1609.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Hart, P. D., and I. Sutherland. 1977. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br. Med. J.2:293-295.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Horwitz, M. A., and G. Harth. 2003. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun.71:1672-1679.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Horwitz, M. A., G. Harth, B. J. Dillon, and S. Maslesa-Galic. 2000. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA97:13853-13858.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    McConkey, S. J., et al. 2003. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med.9:729-735.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    McShane, H., et al. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med.10:1240-1244.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Moorthy, V., et al. 2004. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis.189:2213-2219.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Palmer, C. E., and M. W. Long. 1966. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am. Rev. Respir. Dis.94:553-568.
    OpenUrlPubMedWeb of Science
  15. 15.↵
    Raviglione, M. C., D. E. Snider, Jr., and A. Kochi. 1995. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA273:220-226.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs
A. Williams, N. P. Goonetilleke, H. McShane, Simon O. Clark, Graham Hatch, S. C. Gilbert, A. V. S. Hill
Infection and Immunity May 2005, 73 (6) 3814-3816; DOI: 10.1128/IAI.73.6.3814-3816.2005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs
A. Williams, N. P. Goonetilleke, H. McShane, Simon O. Clark, Graham Hatch, S. C. Gilbert, A. V. S. Hill
Infection and Immunity May 2005, 73 (6) 3814-3816; DOI: 10.1128/IAI.73.6.3814-3816.2005
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antigens, Bacterial
BCG vaccine
Poxviridae
tuberculosis
Vaccines, Synthetic

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522